An Evaluation of the Diagnostic Accuracy of a Panel of Variants in <i>DPYD</i> and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities
Efficacy of 5-Fluorouracil (5-FU)-based chemotherapy is limited by significant toxicity. Tests based upon variants in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines with high level evidence of a link to dihydropyrimidine dehydrogenase (DPD) phenotype and 5-FU toxicity are...
Main Authors: | Claire Palles, Susan Fotheringham, Laura Chegwidden, Marie Lucas, Rachel Kerr, Guy Mozolowski, Dan Rosmarin, Jenny C. Taylor, Ian Tomlinson, David Kerr |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/7/1497 |
Similar Items
-
Investigation of Ivs14+1G>A Polymorphism of Dpyd Gene in a Group of Bosnian Patients Treated with 5-Fluorouracil and Capecitabine
by: Timur Cerić, et al.
Published: (2010-05-01) -
<i>DPYD</i> Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
by: Theodore J. Wigle, et al.
Published: (2023-01-01) -
Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (<i>DPYD</i>) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
by: Paula Soria-Chacartegui, et al.
Published: (2021-11-01) -
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
by: David K. Lau, et al.
Published: (2023-04-01) -
Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
by: Nedal Bukhari, et al.
Published: (2021-07-01)